Literature DB >> 67211

Serologic identification of multiple tumor-associated antigens on murine sarcomas.

G A Parker, S A Rosenberg.   

Abstract

The humoral immune response to two transplanted chemically induced murine sarcomas (MCA-2 and MCA-3) was studied in C57BL/6N mice. These tumors were immunogenic as evidenced by tumor amputation and rechallenge experiments, and no cross-reactivity between them was observed in in vivo challenge experiments. Utilizing a complement-dependent microcytotoxicity assay, we detected antibody to both MCA-2 and MCA-3 in the sera of animals bearing MCA-3 as well as after tumor removal. The sera of animals hyperimmunized to MCA-3 (MCA-3HI) was also cytotoxic in high titer to both MCA-2 and MCA-3 (50% cytotoxicity titers of 1:80 and 1:320, respectively). Sequential absorptions of sera from animals bearing MCA-3 and MCA-3HI sera with fresh MCA-2 cells completely removed activity against MCA-2 but retained reactivity to MCA-3. Sequential absorptions with fresh MCA-3 cells produced stepwise reductions of activity against both tumors, whereas absorption with normal cells produced no loss of activity against either tumor. Thus both specific and cross-reactive antigens were expressed on the surfaces of MCA-3 cells. Only the specific tumor antigen appeared to be involved in in vivo protection against tumor challenge.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 67211     DOI: 10.1093/jnci/58.5.1303

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  14 in total

1.  Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor.

Authors:  T J Eberlein; M Rosenstein; P Spiess; R Wesley; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

2.  Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor alpha in normal and tumor-bearing mice.

Authors:  J A Krosnick; J K McIntosh; J J Mulé; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Improved in vivo efficacy of tumor-infiltrating lymphocytes after restimulation with irradiated tumor cells in vitro.

Authors:  U L Burger; M P Chang; M Nagoshi; P S Goedegebuure; T J Eberlein
Journal:  Ann Surg Oncol       Date:  1996-11       Impact factor: 5.344

4.  Synergistic antitumor activity of cyclophosphamide and ABPP in the treatment of established and advanced tumors in murine tumor models.

Authors:  A M Eggermont; P H Sugarbaker; R L Marquet; J Jeekel
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.

Authors:  J J Mulé; S L Schwarz; A B Roberts; M B Sporn; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models.

Authors:  A M Eggermont; P H Sugarbaker; R L Marquet; J Jeekel
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells.

Authors:  A Eisenthal; H Kashtan; M Rabau; V Ramakrishna; S Chaitchik; Y Skornick
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

8.  Antitumor effect of recombinant tumor necrosis factor-alpha against murine sarcomas at visceral sites: tumor size influences the response to therapy.

Authors:  J J Mulé; A Asher; J McIntosh; R Lafreniere; E Shiloni; A Lefor; C M Reichert; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

9.  Antitumor activity of recombinant interleukin 6 in mice.

Authors:  J J Mulé; J K McIntosh; D M Jablons; S A Rosenberg
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

10.  Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model.

Authors:  A M Eggermont; P H Sugarbaker
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.